

## **LEFRUSID®** **FUROSEMIDE TABLETS**

### **COMPOSITION:**

**Lefrusid® tablets:** Each tablet contains Furosemide BP 40mg.

### **MODE OF ACTION:**

**Lefrusid®** contains furosemide, a 4-chloro-N-furfuryl-5-sulphamoyl anthranilic acid which is a potent, rapid action diuretic. It acts by inhibiting the reabsorption of sodium and chloride ions at the ascending limb of the loop of henle. Other minor sites of action includes proximal and distal tubules. The action at distal tubule is independent of any inhibitory effect on carbonic anhydrase and aldosterone.

### **PHARMACOKINETICS:**

Furosemide is fairly rapidly absorbed from gastrointestinal tract. Bioavailability is about 60% to 70% but absorption, is variable and erratic. The half-life of furosemide is upto 2 hours but is prolonged in neonates, elderly, patients with renal and hepatic insufficiency.

Furosemide is highly albumin bound upto 99%. It is mainly excreted via urine, largely unchanged, small amount is excreted via bile.

Furosemide crosses the placental barrier and it should be used with caution especially the first trimester.

It is also excreted through breast milk.

### **INDICATIONS:**

**Lefrusid®** is indicated for the management of the following:-

1. Oedema associated with congestive heart failure, cirrhosis of the liver, renal disease and nephrotic syndrome. In all these cases, Furosemide tablet is the first choice of treatment.
2. **Lefrusid®** tablet is indicated in hypertension often in combination with other antihypertensives.
3. Renal insufficiency.

### **ADMINISTRATION AND DOSAGE:**

#### **ADULTS:**

##### **Oedema:**

20 to 80mg in a single dose or depending on response to be repeated after 6 to 8 hours in increments of 20 to 40mg once or twice daily.

##### **Hypertension:**

40 to 80mg daily by mouth either alone or in conjunction with other anti-hypertensives.

##### **Renal insufficiency:**

Initial 250mg may be given by mouth increased if necessary in steps of 250mg every 4 to 6 hours to a maximum of 1.5g in 24 hours.

**CHILDREN:** Usual doses: 1 to 3mg/kg body weight upto a maximum of 40mg daily.

### **CONTRA-INDICATIONS:**

Furosemide is contra-indicated in:

1. Patients who are hypersensitive to furosemide.
2. Anuria or in renal failure due to nephrotoxic or hepatotoxic drugs.
3. Renal failure associated with hepatic coma.
4. Pre-comatose states associated with hepatic cirrhosis.

### **PRECAUTION / WARNING:**

1. Use with caution in patients with severe renal and hepatic insufficiency.
2. Furosemide may increase the toxicity of digitalis in cardiac failure patients (see interactions).

### **ADVERSE EFFECTS:**

Fluid and electrolyte imbalance including hyponatraemia, hypokalaemia due to large doses or prolonged administration, ototoxicity which is dependent on plasma concentration. Other side effects include allergy, nausea, diarrhoea, blurred vision, yellow vision, dizziness, headache, skin rashes, photosensitivity and pancreatitis. Furosemide may also provoke hyperglycaemia and glycosuria. It may also precipitate hyperuricaemia worsening gout.

### **INTERACTIONS:**

Furosemide is known to interact with a number of drugs. It increases the toxicity of lithium, digitalis and theophylline. It decreases arterial responsiveness of adrenaline. It antagonizes skeletal muscle relaxant effects of tubocurarine.

### **PREGNANCY AND LACTATION:**

Furosemide crosses placental barrier and hence its use should be carefully monitored during pregnancy especially first trimester. Patients are advised to consult their doctor.

**LEGAL CATEGORY:** Prescription Only Medicine (POM).

**THERAPEUTIC CATEGORY:** ATC: C03C (High-ceiling Diuretic).

**STORAGE CONDITIONS:** Store in a dry place below 30°C. Protect from light. Keep out of reach of children.

**SHELF LIFE:** As per product label.

**PRESENTATION:** **Lefrusid®** tablets are available in blister packs of 100 tablets and in bulk packs of 1000 tablets.

**Date of last Review:** March 2017

**LICENCE HOLDER:** LABORATORY & ALIED LTD.



**Manufactured by:**

**Laboratory & Allied Ltd.**

Plot No. 209/10349, Mombasa Road.

P.O. Box 42875, Nairobi, Kenya.

**LTL040-00**